Dr. Stephen B. Ruddy Ph.D. Net Worth

Dr. Stephen B. Ruddy Ph.D. biography

Dr. Stephen B. Ruddy Ph.D. is the Sr. VP & Chief Technical Officer at Deciphera Pharmaceuticals Inc.

What is the salary of Dr D?

As the Sr. VP & Chief Technical Officer of Deciphera Pharmaceuticals Inc, the total compensation of Dr D at Deciphera Pharmaceuticals Inc is $601,540. There are 13 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of $9,025,190.

How old is Dr D?

Dr D is 57, he's been the Sr. VP & Chief Technical Officer of Deciphera Pharmaceuticals Inc since . There are 12 older and 8 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.

What's Dr D's mailing address?

Stephen's mailing address filed with the SEC is 500 Totten Pond Road, 6th Floor, Waltham, MA 02451, United States.

Insiders trading at Deciphera Pharmaceuticals Inc

Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar, and Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.

What does Deciphera Pharmaceuticals Inc do?

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Deciphera Pharmaceuticals Inc executives and stock owners

Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Steven Hoerter,
  President, Chief Executive Officer, Director
• Michael Taylor,
  Director
• Matthew Sherman,
  Executive Vice President, Chief Medical Officer
• Thomas Kelly,
  Chief Financial Officer, Executive Vice President, Treasurer
• Steven L. Hoerter,
  Pres, CEO & Director
• Daniel Flynn,
  Founder, Executive Vice President, Chief Scientific Officer
• Dr. Matthew L. Sherman,
  Exec. VP & Chief Medical Officer
• Ron Squarer,
  Independent Director
• Frank Friedman,
  Independent Director
• Thomas Patrick Kelly J.D.,
  Exec. VP, CFO & Treasurer
• Dr. Matthew L. Sherman M.D.,
  Exec. VP & Chief Medical Officer
• Dr. Daniel L. Flynn,
  Exec. VP, Chief Scientific Officer & Founder
• Daniel C. Martin,
  Sr. VP & Chief Commercial Officer
• Dr. Stephen B. Ruddy Ph.D.,
  Sr. VP & Chief Technical Officer
• Susan Kelley,
  Independent Director
• James Bristol,
  Independent Chairman of the Board
• Edward Benz,
  Independent Director
• Patricia Allen,
  Independent Director
• Dennis Walsh,
  Independent Director
• John Martin,
  Independent Director
• Melissa Forst,
  IR Contact Officer
• Lisa Amaya Price,
  Sr. VP & Chief HR Officer
• Jennifer Larson,
  Sr. VP of Fin. & Investor Relations
• Margarida Duarte,
  Sr. VP & Head of International
• Jama Pitman,
  Sr. VP of Regulatory, Quality & Portfolio Management
• Jeffrey M. Held J.D.,
  Sr. VP & Gen. Counsel
• Jennifer Robinson,
  VP of Investor Relations
• Dashyant Dhanak,
  EVP & Chief Scientific Officer
• Leaf Venture Management Iii...,
  
• Liam Ratcliffe,
  Director
• Associates Llc Brightstar,
  10% owner
• Christopher John Morl,
  Chief Business Officer
• Michael Jay Ross,
  Director
• Oliver Rosen,
  Chief Medical Officer
• Stephen B. Ruddy,
  Chief Technical Officer
• Daniel C. Martin,
  Chief Commercial Officer
• Jama Pitman,
  SVP, Chief Development Officer